Other Deductions - Net (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Apr. 01, 2012		Apr. 03, 2011
Other (Income) Deductions - Net [Line Items]
Interest income	$ (81)	[1]	$ (105)	[1]
Interest expense	390	[1]	458	[1]
Net interest expense	309		353
Royalty-related income	(97)		(171)
Net gains on asset disposals	(7)		(12)
Certain legal matters, net	814	[2]	501	[2]
Certain asset impairment charges	432	[3]	157	[3]
Other, net	206		(1)
Other deductions-net	$ 1,657		$ 827

[1] Interest income decreased in 2012 due to lower interest rates earned on investments. Interest expense decreased in 2012 due to lower long- and short-term debt balances and the effective conversion of some fixed-rate liabilities to floating-rate liabilities by using interest rate swaps.

[2] In 2012, primarily relates to a $450 million charge in connection with an agreement-in-principle to settle a lawsuit by Brigham Young University related to Celebrex and charges for hormone-replacement therapy litigation. In 2011, primarily relates to charges for hormone-replacement therapy litigation (see Note 12. Commitments and Contingencies).

[3] In 2012, primarily includes intangible asset impairments of approximately $395 million reflecting (i) $297 million of in-process research and development (IPR&D) that targeted autoimmune and inflammatory diseases, (ii) $45 million related to our Consumer Healthcare indefinite-lived brand, Robitussin, and (iii) $53 million of developed technology rights comprising the impairments of two assets. See also the table below. In 2011, relates to IPR&D for the treatment of a certain autoimmune and inflammatory disease. The impairment charges reflect, among other things, the impact of new scientific findings for IPR&D, and an increased competitive environment for Robitussin.